MEDTRONIC PLC
MDTNYSETrading Snapshot
- Day Range
- $86.37 β $88.77
- 52-Week Range
- $73.31 β $106.33
- Volume
- $4.41B
- Avg Volume
- $4.98B
- Shares Outstanding
- 1.28B
- Next Earnings
- Nov 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $36.36B
- Last Q Revenue
- $9.76B
- P/E Ratio
- 21.7
- P/S Ratio
- 3.0x
- EPS (TTM)
- $4.06
- Dividend Yield
- 3.22%
- Dilution (1yr)
- β0.2%
Why Investors Own MDT
- βHigh-growth profile β revenue up +25.5% YoY with expanding US Equity exposure.
- βHealthy economics β 78% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MEDTRONIC PLC
MDTAbout MEDTRONIC PLC
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
MEDTRONIC PLC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift MDT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
MEDTRONIC PLC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.